AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27121262
Drug: Ixazomib 2.3
RxNorm normalized name: ixazomib 2.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib 2.3 mg (moderate hepatic impairment)
Trial: 27121262
Drug: Ixazomib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib 1.5 mg (severe hepatic impairment)
Trial: 27121262
Drug: Recommended starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recommended starting dose for ixazomib
Trial: 17425550
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) via vacuum-assisted closure (VAC) device
Trial: 21129474
Drug: Standard wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard wound therapy (SWT)
Trial: 19880578
Drug: 4‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐mg nicotine lozenge
Trial: 9459471
Drug: Cocaine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 0.4 mg/kg
Trial: 9459471
Drug: Cocaine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 0.2 mg/kg
Trial: 2145791
Drug: Procaterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol (10 micrograms/inhalation)
Trial: 2145791
Drug: Albuterol (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (90 micrograms/inhalation)
Trial: 30922873
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid 5 to 10 mg or 10 mg once daily for 12 months, followed by variable adjusted doses during the open-label extension.
Trial: 19402182
Drug: Captopril LPH
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril LPH 25 mg
Trial: 19402182
Drug: Captopril LPH
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril LPH 50 mg
Trial: 19402182
Drug: Capoten 50
RxNorm normalized name: Capoten 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capoten 50 mg
Trial: 15213582
Drug: Methylphenidate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate plus psychosocial treatment (academic remediation, organizational skills training, psychotherapy, parent training, counseling, social skills training)
Trial: 15213583
Drug: Methylphenidate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate plus attention control treatment
Trial: 9691878
Drug: 0.2% ropivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine, 8 ml/h for 24 hours
Trial: 9691878
Drug: 0.2% bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% bupivacaine, 8 ml/h for 24 hours
Trial: 8964876
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg E2 valerate
Trial: 6426830
Drug: Naloxone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.2 mg/kg)
Trial: 7307425
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg propranolol intravenously (group 1)
Trial: 31624837
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg once daily for 16 weeks
Trial: 30073766
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 16 weeks
Trial: 31912462
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg once daily
Trial: 31411762
Drug: DEX infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX infusion 0.5 μg/kg after delivery and PCIA with DEX plus sufentanil
Trial: 31411762
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (infusion with 0.9% normal saline after delivery and PCIA with sufentanil)
Trial: 28146613
Drug: Aripiprazole Once-Monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole Once-Monthly 400 mg (AOM 400)
Trial: 21724580
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2 g/d)
Trial: 17492350
Drug: Conjugated Hib
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated Hib vaccine
Trial: 15145966
Drug: Anidulafungin 50
RxNorm normalized name: anidulafungin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin 50 mg, 75 mg, or 100 mg daily intravenous infusions preceded by a loading dose that was twice the daily dose.
Trial: 8770428
Drug: Regular neuroleptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular neuroleptic medication
Trial: 18245030
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from medication
Trial: 678769
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic cover
Trial: 19294859
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy group
Trial: 17933158
Drug: Milrinone (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (bolus and infusion throughout surgery)
Trial: 12149533
Drug: AS+NRT (Nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS+NRT (Nicotine patches daily and inhalator as needed plus advice and support)
Trial: 1934240
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg body weight twice daily) for 1 day (3 doses)
Trial: 1934240
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg body weight twice daily) for 2 days
Trial: 1934240
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg body weight twice daily) for 4 days
Trial: 1934240
Drug: Quinine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (10 mg/kg body weight twice daily) for 7 days
Trial: 7106043
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 20-percent lipofundin followed by ergometer load (group II)
Trial: 7106043
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of lipofundin without subsequent physical stress (group III)
Trial: 27085783
Drug: Metformin 850mg
RxNorm normalized name: METFORMIN 850MG/PIOGLITAZONE 15MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850mg twice daily
Trial: 21592974
Drug: UACR in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UACR in the fourth quartile (≥ 6.1 mg/g)
Trial: 21592974
Drug: UACR in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UACR in the third quartile (3.8-6.1 mg/g)
Trial: 21592974
Drug: UACR in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UACR in the lowest quartile (<2.8 mg/g)
Trial: 17122382
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 5 mg twice daily
Trial: 17122382
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 10 mg twice daily
Trial: 9558692
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy for rate control
Trial: 9558692
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy for rhythm control
Trial: 9558692
Drug: Drug selection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug selection algorithm for rate control
Trial: 24460645
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg once daily for 35 ± 4 days
Trial: 31655496
Drug: Prednisone administration
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone administration
Trial: 31655496
Drug: Prednisolone administration
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone administration
Trial: 26674499
Drug: Daily 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 400 IU vitamin D supplementation
Trial: 16243339
Drug: Calcium (600
RxNorm normalized name: calcium carbonate/vitamin D3 250 mg calcium (600 mg)-125 unit ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (600 mg) plus CLA (450 mg)
Trial: 10333943
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of family history, fasting glucose, and total proinsulin
Trial: 2190549
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pyridostigmine bromide every 8 h
Trial: 379704
Drug: Carfecillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfecillin (250 mg and 500 mg p.o.)
Trial: 27123977
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy based on the catastrophic cognitions model of PDA
Trial: 27123977
Drug: Guided mastery
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided mastery (guided exposure) therapy based on the self-efficacy model of PDA
Trial: 9892856
Drug: Amisulpride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50 mg/day)
Trial: 9892856
Drug: Amineptine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amineptine (200 mg/day)
Trial: 2572494
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg etizolam
Trial: 28698258
Drug: Standard-dose enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose enoxaparin
Trial: 26408319
Drug: Yerba Mate
RxNorm normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yerba Mate supplementation (3 g/day, 3 capsules per meal, 3 times a day for 12 weeks)
Trial: 23506627
Drug: Residual protein/creatinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual protein/creatinine ratio (rPCR) <1000 mg/g
Trial: 23506627
Drug: Residual estimated
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual estimated glomerular filtration rate (reGFR) ≥45 mL/min per 1.73 m2
Trial: 23506627
Drug: Residual protein/creatinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual protein/creatinine ratio (rPCR) between 1000-<2000 mg/g and reGFR ≥30 mL/min per 1.73 m2
Trial: 23506627
Drug: Residual estimated
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual estimated glomerular filtration rate (reGFR) <30 mL/min per 1.73 m2 and rPCR ≥2000 mg/g
Trial: 19445552
Drug: Sublingual morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual morphine sulphate 0.5 mg/kg (Group A)
Trial: 19445552
Drug: Sublingual midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sublingual midazolam 0.03 mg/kg (Group B)
Trial: 18508950
Drug: Taranabant 5
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 5 mg once daily for 14 days
Trial: 18508950
Drug: Taranabant 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 7.5 mg once daily for 14 days
Trial: 18508950
Drug: Taranabant 10
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 10 mg once daily for 14 days
Trial: 18508950
Drug: Taranabant 25
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 25 mg once daily for 14 days
Trial: 16077888
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and G-CSF (group A)
Trial: 16077888
Drug: Antibiotics only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics only (group B)
Trial: 8829859
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg.kg-1
Trial: 7484022
Drug: Adenosine 50
RxNorm normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 50 micrograms.kg-1.min-1 + Morphine 0.1 mg.kg-1
Trial: 7484022
Drug: Ketamine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.1 mg.kg-1
Trial: 15533378
Drug: Low-molecular-weight dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight dextran (Dextran 40) infusion
Trial: 15533378
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin infusion
Trial: 2904839
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet alone (Group 1)
Trial: 2904839
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet with 150 ml oral fluid (Group 3)
Trial: 2904839
Drug: Oral ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ranitidine 150 mg with oral fluid 150 ml (Group 4)
Trial: 2904839
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet with IM narcotic and atropine (Group 2)
Trial: 17561543
Drug: Indiplon 15
RxNorm normalized name: Indiplon
DrugBank: Indiplon (DB12590)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indiplon 15 mg nightly
Trial: 10697305
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 16 mg once daily for 6 weeks
Trial: 9108638
Drug: Ropivacaine hydrochloride
RxNorm normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine hydrochloride 20 mg
Trial: 9108638
Drug: Ropivacaine hydrochloride
RxNorm normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine hydrochloride 40 mg
Trial: 9108638
Drug: Ropivacaine hydrochloride
RxNorm normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine hydrochloride 80 mg
Trial: 3814215
Drug: Amcinonide, betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amcinonide, betamethasone 17-valerate, triamcinolone acetonide (alcoholic solutions)
Trial: 3814215
Drug: Clobetasol 17-propionate
RxNorm normalized name: clobetasol 17-propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol 17-propionate (ointment)
Trial: 27156228
Drug: Morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alone (M)
Trial: 27156228
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and morphine (AM)
Trial: 25336916
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg (single oral dose)
Trial: 20825523
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg) daily for 3 months
Trial: 18315942
Drug: Fixed-combination bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-combination bimatoprost 0.03%/timolol 0.5% administered once daily
Trial: 18315942
Drug: Fixed-combination travoprost/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination travoprost/timolol
Trial: 19692375
Drug: Fixed-combination latanoprost/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination latanoprost/timolol
Trial: 14706505
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist therapy (immediate adjuvant therapy after prostatectomy)
Trial: 14706505
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with radiation
Trial: 14706505
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (LHRH agonist + nonsteroidal antiandrogen)
Trial: 14706505
Drug: Intermittent hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent hormone therapy
Trial: 14706505
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist therapy
Trial: 28964314
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg rocuronium
Trial: 12017979
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg rocuronium
Trial: 10998836
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg rocuronium (females)
Trial: 10998836
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg rocuronium (females)
Trial: 10998836
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg rocuronium (females)
Trial: 10998836
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg rocuronium (males)
Trial: 10998836
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg rocuronium (males)
Trial: 10998836
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg rocuronium (males)
Trial: 8844446
Drug: Felbamate (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbamate (1,200 mg every 12 hours)
Trial: 30359684
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg twice daily for seven days
Trial: 24121083
Drug: Ultrasound-guided SIJ
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided SIJ injections
Trial: 24121083
Drug: Fluoroscopy-guided SIJ
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopy-guided SIJ injections
Trial: 22682323
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg three times a week
Trial: 18076292
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (80 mg/12 h)
Trial: 18076292
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg/12 h)
Trial: 9005613
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (thrombolytic drugs, beta‐blockers, APP inhibitors, nitrates, aspirin)
Trial: 6979982
Drug: Propranolol 10
RxNorm normalized name: propranolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 10 mg every 6 hours enterally starting the morning after surgery (Group I, 50 patients)
Trial: 30120033
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (MT) program for sensori‐motor impairment
Trial: 18502028
Drug: Propiverine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine (10 or 15 mg twice daily)
Trial: 17944740
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. + Placebo
Trial: 17944740
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. + Ranitidine 300 mg at bedtime
Trial: 15854087
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral prednisolone once daily perioperatively (Group I, n = 20)
Trial: 12408530
Drug: Induction group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction group (IFN 3 MU daily for 14 days, then 3 MU three times a week)
Trial: 10225553
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (treatment duration up to 48 days)
Trial: 10225553
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (treatment duration 49 or more days)
Trial: 7869940
Drug: dF 30
RxNorm normalized name: AlleRx DF 30-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dF 30 mg acutely (n = 6)
Trial: 7869940
Drug: dF 15
RxNorm normalized name: Adriamycin RDF 150mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dF 15 mg twice daily for 15 days (chronic)